We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Biotech bounce

10 July 2020 By Lisa Jucca

The $11 bln company’s Covid-19 kits may not be as iconic as Prada bags or Ferrari cars. But they sell like hot cakes in a pandemic. If the virus wanes, so will its tests’ appeal. Still, DiaSorin’s biotech focus is a step-up from traditional Made in Italy products.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)